Skip to content

Consequences of Obstructive Sleep Apnea Syndrome (OSAS) After Ischemic Subtentorial Stroke.

Consequences of Obstructive Sleep Apnea Syndrome (OSAS) on the Outcome and the Survival After Ischemic Subtentorial Stroke. Impact of the Treatment With Continuous Positive Airway Pressure (CPAP)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01561677
Enrollment
300
Registered
2012-03-23
Start date
2011-09-30
Completion date
2020-12-31
Last updated
2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Infarction, Obstructive Sleep Apnea Syndrome

Keywords

obstructive sleep apnea, syndrome survival, ischemic stroke, continuous positive airway pressure, handicap

Brief summary

Obstructive Sleep Apnea Syndrome (OSAS) is associated with stroke as a risk factor but little is known about the consequences of OSAS on the outcome and the survival after stroke. The aim of the investigators study is first to evaluate the outcome and the survival of patients with stroke depending of OSAS (presence and severity of OSAS) and second to compare the outcome and survival of patients with severe OSAS depending on the treatment of the syndrome with nocturnal continuous positive airway pressure. The investigators hypothesis is that OSAS is associated with worst survival and outcome and needs to be treated at the subacute phase of stroke.

Detailed description

Objective : The aim of our study is to evaluate the consequences of obstructive sleep apnea syndrome on the functional outcome and the survival after an ischemic stroke and to measure the impact of the treatment with continuous positive airway pressure on the outcome of patients with severe obstructive sleep apnea syndrome.Patients and methods : We will prospectively explore by polysomnography, 300 consecutive patients hospitalized for an ischemic stroke in the stroke units of university hospitals at the sub acute phase after stroke (J15±4). 1) We will compare the functional outcome, the neurological impairment, the peripheral endothelial function, the continuous blood pressure measure on 24 hours recording, the quality of life and the survival at 3, 6 and 12 months in four groups of patients depending on their apnea/hypopnea index 2) In patients with severe obstructive sleep apnea syndrome, we will explore the impact on the functional outcome, the neurological impairment, and the survival at 3, 6 et 12 months of a treatment with continuous positive airway pressure (CPAP) randomly compared to a treatment with sham CPAP (non efficacious pressure) during 3 months. Conclusion : This study should allow us to evaluate the consequences of obstructive sleep apnea syndrome on the outcome and the survival after ischemic stroke and the impact and the tolerance of the treatment with continuous positive airway pressure in patients with severe obstructive sleep apnea syndrome.

Interventions

DEVICEContinuous Positive Airway pressure-RESPIRONICS

obstructive sleep apnea syndrome survival ischemic stroke continuous positive airway pressure handicap

DEVICESham Continuous Positive Airway pressure-RESPIRONICS

inefficient Continuous Positivie Airway pressure

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Brain infarction confirmed by brain imaging * follow up possible * Severity at admission and at one week follow up: * NIHSS ≥ 4 or- isolated aphasia (item 9 ofNIHSS ≥ 1) or * negligence (item 11 du NIHSS ≥ 2) or * distal motor deficit (score ≥ 1) * Health insurance affiliation * Inform and free consent agreement

Design outcomes

Primary

MeasureTime frameDescription
functional independence scale3 monthsThe variation of the functional independence scale is evaluated by the Barthel Index at three months after stroke in four groups of patients depending on their apnea/hypopnea.In the patients group severe OSAS treated with CPAP from day 15 after stroke compared to patients with severe OSAS treated with sham CPAPThe neurological dependency will be evaluated by the Barthel Index .This scale measures the consequences of the motor and cognitive disorders on the daily living with 10 items.

Secondary

MeasureTime frameDescription
neurological impairment3 monthsThe variation of the neurological impairment (NIHSS score) at three months after stroke: * in four groups of patients depending on their apnea/hypopnea index * In the patients group with severe OSAS treated with CPAP from day 15 after stroke vs patients with severe OSAS treated with sham CPAP
the handicap3 monthsthe handicap (via the Rankin score ), at three months after stroke: in four groups of patients depending on their apnea/hypopnea index In the patients group with severe OSAS treated with CPAP from day 15 after stroke vs patients with severe OSAS treated with sham CPAP
blood pressure3 monthsThe continuous measure of blood pressure over 24 hours at three months after stroke: in four groups of patients depending on their apnea/hypopnea index In the patients group with severe OSAS treated with CPAP from day 15 after stroke vs patients with severe OSAS treated with sham CPAP
the quality of life3 monthsthe quality of life (SF-36) at three months after stroke: in four groups of patients depending on their apnea/hypopnea index In the patients group with severe OSAS treated with CPAP from day 15 after stroke vs patients with severe OSAS treated with sham CPAP
the survival3 monthsthe survival at three months after stroke: in four groups of patients depending on their apnea/hypopnea index In the patients group with severe OSAS treated with CPAP from day 15 after stroke vs patients with severe OSAS treated with sham CPAP

Countries

France

Contacts

Primary ContactYves DAUVILLIERS, MD-PhD
y-dauvilliers@chu-montpellier.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026